Jeffrey Leiden Acquires 5,000 Shares of Odyssey Therapeutics (NASDAQ:ODTX) Stock

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Director Jeffrey Leiden acquired 5,000 shares of the stock in a transaction on Friday, May 8th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $100,000.00. Following the transaction, the director directly owned 270,198 shares in the company, valued at approximately $5,403,960. This trade represents a 1.89% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Odyssey Therapeutics Stock Up 2.6%

ODTX opened at $17.90 on Wednesday. Odyssey Therapeutics, Inc. has a fifty-two week low of $15.35 and a fifty-two week high of $20.30.

Odyssey Therapeutics News Summary

Here are the key news stories impacting Odyssey Therapeutics this week:

• Positive Sentiment: Director Dimension Capital II, L.P. disclosed a large purchase of 1,111,111 shares, increasing its ownership by 50%. This is the biggest recent insider buy and could be seen as a strong vote of confidence. SEC filing
• Positive Sentiment: Director Nan (Ln) Li also bought 1,111,111 shares, another sizable insider purchase that reinforces the bullish insider signal. SEC filing
• Positive Sentiment: Several other insiders added stock, including Director Shelley Chu, CFO Jason Haas, and Director Jeffrey M. Leiden. Coordinated buying across management and the board often supports investor confidence. Article
• Neutral Sentiment: A broader healthcare IPO report noted that healthcare listings raised $4.7 billion, with Odyssey Therapeutics mentioned as one of the IPO debuts that slipped. This is more of a sector market backdrop than a company-specific catalyst. Article
• Negative Sentiment: The only insider sale in the news flow was a small 1,780-share sale by SR One Capital Management, but it was minor compared with the much larger purchases, so it is unlikely to outweigh the bullish effect of the buying. SEC filing